Accelerated Progression Of Hepatocellular Carcinoma During Immunosuppressive Therapy With Abatacept For Rheumatoid Arthritis
INTERNAL MEDICINE(2019)
摘要
Abatacept, a cytotoxic T lymphocyte antigen-4 immunoglobulin recombinant fusion protein, is an immunosuppressive agent indicated for rheumatoid arthritis. Although no significant increase in malignancy has been reported in abatacept-treated patients, whether or not abatacept accelerates tumor progression in specific cancer types remains unclear. We herein report a 66-year-old woman who showed unusually rapid progression of hepatocellular carcinoma following abatacept therapy for rheumatoid arthritis. Abatacept was speculated to have accelerated her hepatocellular carcinoma progression in the setting of her preexisting risk factors: autoimmune hepatitis and long-term methotrexate use. We propose close tumor surveillance be performed during abatacept therapy, especially for high-risk patients.
更多查看译文
关键词
hepatocellular carcinoma, cancer immunity, immunosuppressive therapy, abatacept, cytotoxic T lymphocyte antigen-4 (CTLA-4)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要